Scientific Advisory Board
Cardiovascular Health Experts
Christie M. Ballantyne, M.D.
Dr. Ballantyne is a leading cardiovascular specialist, lipidology expert and atherosclerotic vascular disease researcher. He is currently a Professor of Medicine at Baylor College of Medicine and the Chief of the Sections of Cardiovascular Research and Cardiology. Additionally, Dr. Ballantyne is the Director of The Maria and Alando J. Ballantyne, M.D., Atherosclerosis Clinical Research Laboratory and the Director of the Center for Cardiovascular Disease Prevention at the Methodist DeBakey Heart and Vascular Center as well as the Co-Director of the Lipid Metabolism and Atherosclerosis Clinic at Houston Methodist Hospital.
Dr. Ballantyne has conducted extensive research on the pathophysiology of atherosclerosis, with an emphasis on monocyte activation and adhesion, and led numerous clinical research programs on the prevention of atherosclerotic vascular disease. Dr. Ballantyne earned his degree in medicine from Baylor College of Medicine and performed both his internal medicine residency and postgraduate training at The University of Texas Southwestern Medical School. He completed a cardiology fellowship at Baylor College of Medicine and an American Heart Association/Bugher Foundation Fellowship at the Howard Hughes Medical Institute and Institute for Molecular Genetics at Baylor. Dr. Ballantyne is published extensively, speaks nationally and internationally on lipids, atherosclerosis and inflammation, and serves as an Editorial Director for www.lipidsonline.org. In 2014, he was recognized by Thomson Reuters as one of The World's Most Influential Scientific Minds.
John J.P. Kastelein, M.D., Ph.D., FESC
Dr. John Kastelein is Professor of Medicine and Chairman of the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease. Dr. Kastelein is a recognized world leader in studies focused on the significance of lipoprotein metabolism in the development of atherosclerotic vascular disease. Dr. Kastelein's current research interests focus on the etiology, diagnosis, prevention, and treatment of hypertriglyceridemia, hypercholesterolemia, and low HDL cholesterol, all conditions associated with atherosclerosis and cardiovascular disease. He has published more than 850 research papers in peer-reviewed journals, including Nature Genetics, Lancet, New England Journal of Medicine, JAMA, and Circulation. His Hirsch index is 114 as of March 2018; and his total citations are approaching more than 60,000.
Dr. Kastelein founded the Lipid Research Clinic at the Academic Medical Centre in Amsterdam in 1989, which is currently serving as a tertiary referral center for over 5000 patients each year and has become part of the Department of Vascular Medicine. Dr. Kastelein was President of the Dutch Atherosclerosis Society (DAS) and chairs the National Scientific Committee on Familial Hypercholesterolemia (EHC). He also is a member of the Royal Dutch Society for Medicine & Physics, the Council for Basic Science of the American Heart Association and the European Atherosclerosis Society, and a Fellow of the European Society of Cardiology. He also is a board member of the International Task Force for CHD Prevention and was recently appointed to the Executive Board of the International Atherosclerosis Society (IAS). In addition to the scientific programs aimed at the etiology of atherogenesis, Dr. Kastelein also served on a number of executive and steering committees of large cardiovascular intervention studies, including the SPIRE, ORION, GLAGOV, REALIZE, IDEAL, TNT, CAPTIVATE, ENHANCE, ILLUMINATE, JUPITER, RADIANCE and numerous others of which TNT (2005), RADIANCE 1 (2007), ENHANCE (2008), JUPITER (2008), SPIRE and ORION (2017) are published in the New England Journal of Medicine, IDEAL (2006) and GLAGOV (2017) in JAMA and RADIANCE 2 (2007) and REALIZE (2016) in Lancet.
Kevin C. Maki, Ph.D.
Dr. Kevin Maki is a leading clinical lipid specialist with extensive experience in the design and conduct of clinical trials in human nutrition, metabolism and chronic disease management. He has participated in more than 250 clinical trials and observational studies as an investigator, consultant or statistician. Dr. Maki is the Founder and Chief Scientist for the Midwest Biomedical Research Center for Metabolic and Cardiovascular Health and Adjunct Faculty in Biostatistics and Applied Epidemiology at DePaul University in Chicago. He is a certified Clinical Lipid Specialist and a Fellow of the National Lipid Association, The Obesity Society and the American College of Nutrition, as well as a Vice President of the Board of Governors of the Accreditation Council for Clinical Lipidology.
Dr. Maki's research has been extensively published in more than 200 peer reviewed scientific papers and he has authored or co-authored several books, including Practical Lipid Management: Concepts and Controversies and Therapeutic Lipidology. He also served as a member of the Expert Panel and Writing Group that developed the National Lipid Association's Recommendations for Patient-Centered Management of Dyslipidemia: Parts 1 and 2.
Harold E. Bays, M.D.
Dr. Bays is Board Certified in Endocrinology and Internal Medicine, Diplomate of the American Board of Clinical Lipidology, and Diplomate of the American Board of Obesity Medicine. He is the Founder of Your Body Goal, where he oversees a state-of-the art weight management program and also serves as Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center. He has written or served as a contributing author to over 200 peer-reviewed scientific manuscripts and book chapters, well as presented over 100 scientific abstracts at major scientific meetings and is frequently invited as a national and international speaker. He has served as first author for a number of scientific consensus statements in Lipidology and Obesity Medicine and was lead author of the National Lipid Association Annual Summary of Clinical Lipidology 2015 & 2016, co-author of the National Lipid Association Recommendations for Patient-Centered Treatment of Dyslipidemia, and Chairman of the Obesity Medicine Association Obesity Algorithm.
Over the course of his career, Dr. Bays has served as an Investigator for over 500 early to late-stage clinical trials evaluating treatments for dyslipidemias, obesity, diabetes mellitus, hypertension, and other metabolic and hormonal disorders. He served as Chairman of the National Lipid Association 2012 Adiposity and Dyslipidemia Consensus Conference and Chairman of the 2010 American Association of Clinical Endocrinologist Adipose Tissue Pathophysiology State of the Science Conference. He has served as Chairman and task force member for a number of other medical initiatives regarding lipids and obesity and has received several scientific awards in such as the 2016 Obesity Medicine Association "Obesity Medicine Clinician of the Year," 2015 National Lipid Association "President's Service Award," and 2014 American Society of Bariatric Physicians "Task Force Award."
Dr. Bays is a Fellow of the National Lipid Association (FNLA), Fellow of The Obesity Society (FTOS), Fellow of the American College of Cardiology (FACC) and Fellow of the American Association of Clinical Endocrinologists (FACE).
James A. Underberg, M.D., M.S., FACPM, FACP, FNYAM, FASPC, FNLA
Dr. Underberg is a Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease. He is also the Director of the Bellevue Hospital Lipid Clinic. Dr. Underberg holds joint appointments in the divisions of General Internal Medicine and Endocrinology at NYU.
Dr. Underberg is a Diplomate of the American Board of Clinical Lipidology and Immediate Past-President of the National Lipid Association. He is a Fellow of the National Lipid Association and President of the American Board of Clinical Lipidology. He serves on the editorial board of the Journal of Clinical Lipidology and is a board member of the National Lipid Association, the Foundation of the National Lipid Association, The American Society of Preventive Cardiology and the American Board of Clinical Lipidology. Dr. Underberg also serves on the scientific advisory board of the Familial Hypercholesterolemia (FH) Foundation.
Dr. Underberg's clinical focus is preventive cardiovascular medicine, where he specializes in the management of patients with lipids and lipoprotein disorders, hypertension management, and cardiovascular disease prevention. He maintains an active clinical research program in these areas and has authored numerous articles and book chapters in the field of clinical lipidology. Dr. Underberg has a Bachelor of Science and Master of Science from Yale University, and a medical degree from the Perelman School of Medicine at the University of Pennsylvania. His internship and residency were completed at Bellevue Hospital Medical Center.